NRG2

NRG2 is an EGF-family ligand that signals through ErbB3 and ErbB4 receptors to regulate cell proliferation, migration, and survival in neural, vascular, and cardiac tissues. NRG2 binds directly to ErbB3 and ErbB4 but not ErbB1 or ErbB2, transactivating ErbB heterodimers and stimulating downstream PI3K-Akt signaling (PMID:9866830, PMID:40584443). Independent of its EGF-like domain, the N-terminal Ig-like domain of NRG2 inhibits endothelial cell proliferation by preventing Rb hyperphosphorylation and exerts anti-angiogenic activity in vivo (PMID:14722120). NRG2 protein levels are controlled by HECW1-mediated ubiquitination at K223, a process promoted by NDRG1, and degradation of NRG2 through this axis reverses EGFR TKI resistance in NSCLC cells (PMID:41193668).

1. 1997 High

   Identification of NRG2 as a novel ErbB ligand resolved whether additional neuregulin family members existed and established its capacity to activate ErbB2, ErbB3, and ErbB4 phosphorylation, with a distinctive brain-restricted expression pattern.

   Evidence Cloning and receptor tyrosine phosphorylation assays in transfected cells

   PMID:9199335

   Open questions at the time

   • Receptor binding specificity not yet resolved (direct vs. indirect phosphorylation)
   • Downstream signaling pathways not characterized
   • In vivo function unknown
2. 1998 High

   Direct binding studies clarified that NRG2 engages ErbB3 and ErbB4 but not ErbB1 or ErbB2, and transactivates heterodimer pairs, establishing its receptor selectivity as distinct from NRG1.

   Evidence Radiolabeled competitive binding assay and receptor transactivation assay using recombinant soluble NRG2

   PMID:9866830

   Open questions at the time

   • No crystal structure of the NRG2–receptor complex
   • Mechanism by which NRG2 transactivates heterodimers containing ErbB1/ErbB2 without direct binding unclear
   • Physiological relevance in vivo not tested
3. 2004 High

   Domain dissection revealed that the Ig-like domain, not the EGF-like domain, mediates anti-proliferative and anti-angiogenic effects, uncoupling receptor-activating and non-canonical functions of NRG2.

   Evidence Domain deletion constructs tested in endothelial cell proliferation, cell cycle (Rb phosphorylation), and chick chorioallantoic membrane angiogenesis assays

   PMID:14722120

   Open questions at the time

   • Receptor or binding partner for the Ig-like domain not identified
   • Mechanism linking Ig-like domain to Rb hypophosphorylation unknown
   • Relevance to tumor vasculature not tested in mammalian models
4. 2019 Medium

   Demonstration that NRG2 activates ErbB4–Akt signaling and promotes neuronal migration connected this ligand to a defined intracellular cascade in a neural context.

   Evidence Western blot for pErbB4 and pAkt1 with dose-response, scratch wound healing assay in HT22 neurons

   PMID:40584443

   Open questions at the time

   • Single cell line, awaits replication in primary neurons
   • No genetic loss-of-function in this study
   • Contribution of ErbB3 vs. ErbB4 heterodimers not resolved
5. 2025 Medium

   Identification of HECW1 as the E3 ligase ubiquitinating NRG2 at K223, promoted by NDRG1, established the first post-translational regulatory mechanism controlling NRG2 protein turnover and linked it to EGFR TKI resistance.

   Evidence Site-specific ubiquitination assays, protein interaction studies, and in vivo xenograft experiments in NSCLC models

   PMID:41193668

   Open questions at the time

   • Single lab; HECW1-NRG2 interaction awaits independent confirmation
   • Whether ubiquitination occurs on membrane-tethered or shed NRG2 is unresolved
   • Structural basis for NDRG1-mediated promotion of HECW1 activity unknown
6. 2025 Medium

   Macrophage-derived NRG2 was shown to signal through cardiomyocyte ErbB4 to protect against hypertrophy and restore mitochondrial bioenergetics, establishing a paracrine cardioprotective role. (preprint)

   Evidence Nrg2 knockdown in macrophages, recombinant NRG2 treatment, multi-omics, and mouse pressure-overload model

   PMID:bio_10.1101_2025.05.22.655661

   Open questions at the time

   • Preprint; awaits peer review
   • Whether NRG2 is required in vivo (conditional knockout) not shown
   • Relative contribution of NRG2 vs. NRG1 in cardiac protection not delineated

• The receptor or binding partner mediating the anti-angiogenic activity of the NRG2 Ig-like domain remains unidentified, and in vivo genetic studies of NRG2 function in brain, heart, and vasculature using conditional knockouts are lacking.
• No conditional knockout phenotype reported in any tissue
• No structural model of NRG2 in complex with any receptor
• Physiological relevance of Ig-like domain anti-angiogenic function untested in mammals